Skip to main content

Reno-30 Disease Interactions

There are 5 disease interactions with Reno-30 (diatrizoate).

Major

Radiopaque contrast agents (applies to Reno-30) pheochromocytoma

Major Potential Hazard, Moderate plausibility.

Administration of radiopaque materials to patients known or suspected of having pheochromocytoma should be performed with extreme caution. If, in the opinion of the physician, the possible benefits of such procedures outweigh the considered risk, the procedures should be performed with the absolute minimum amount of injected radiopaque medium. The blood pressure should be assessed throughout the procedure and measures for treatment of a hypertensive crisis should be available.

References

  1. "Product Information. Visipaque (iodixanol)." Nycomed Inc PROD (2001):
  2. "Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc (2006):
  3. "Product Information. Oxilan (ioxilan)." Guerbet LLC (2006):
  4. "Product Information. Hypaque (diatrizoate)." Amersham Health (2007):
  5. "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc (2007):
  6. "Product Information. Cystografin (diatrizoate)." Bristol-Myers Squibb (2015):
  7. "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc (2015):
View all 7 references
Moderate

Diatrizoate (applies to Reno-30) congestive heart failure

Moderate Potential Hazard, Moderate plausibility.

Due to the transitory increase in the circulatory osmotic load, injections with urographic agents should be used with caution in patients with congestive heart failure. Such patients should be observed for several hours following the procedure to detect delayed hemodynamic disturbances.

Moderate

Intravascular contrast agents (applies to Reno-30) multiple myeloma

Moderate Potential Hazard, Moderate plausibility.

A definite risk exists in the use of intravascular contrast agents in patients who are known to have multiple myeloma. In such cases, anuria has developed resulting in progressive uremia, renal failure and eventually death. Although neither the contrast agent nor dehydration has separately proved to be the cause of anuria in myeloma, it has been speculated that the combination of both may be causative factors. The risk in patients with myeloma is not a contraindication to the procedure; however, partial dehydration in the preparation of these patients for the examination is not recommended since this may predispose to precipitation of myeloma protein in the renal tubules. Myeloma, which occurs most commonly in persons over 40, should be considered before instituting intravascular administration of contrast agents.

References

  1. "Product Information. Visipaque (iodixanol)." Nycomed Inc PROD (2001):
  2. "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc (2007):
  3. "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc (2015):
  4. "Product Information. Hexabrix 200 (ioxaglate)." Tyco Healthcare Group Canada Inc (2015):
View all 4 references
Moderate

Iodinated contrast agents (applies to Reno-30) myasthenia gravis

Moderate Potential Hazard, Moderate plausibility.

The administration of iodinated contrast media may aggravate the symptoms of myasthenia gravis. Caution is advised when using these agents in patients with this condition.

References

  1. "Product Information. Visipaque (iodixanol)." Nycomed Inc PROD (2001):
  2. "Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc (2006):
  3. "Product Information. Oxilan (ioxilan)." Guerbet LLC (2006):
  4. "Product Information. Isovue-M-200 (iopamidol)." Bracco Diagnostics Inc (2007):
  5. "Product Information. Conray (iothalamate)." Mallinckrodt Medical Inc (2015):
View all 5 references
Moderate

Iodinated contrast media (applies to Reno-30) asthma/allergies

Moderate Potential Hazard, Moderate plausibility.

Iodinated contrast media such as ioversol, can cause life-threatening or fatal hypersensitivity reactions including anaphylaxis and anaphylactic shock. Manifestations include respiratory arrest, laryngospasm, bronchospasm, angioedema, and shock. Most severe reactions develop shortly after the start of the injection (e.g. within 1 to 3 minutes), but delayed reactions may occur. There is an increased risk in patients with a history of a previous reaction to contrast agent, and known allergies (i.e., bronchial asthma, drug, or food allergies), and other hypersensitivities. Caution is advised on these patients. Premedication with antihistamines or corticosteroids to avoid or minimize possible allergic reactions may reduce both their incidence and severity.

References

  1. "Product Information. Optiray 350 (ioversol)." Mallinckrodt Medical Inc (2006):

Reno-30 drug interactions

There are 168 drug interactions with Reno-30 (diatrizoate).


Report options

Loading...
QR code containing a link to this page

Drug Interaction Classification

These classifications are only a guideline. The relevance of a particular drug interaction to a specific individual is difficult to determine. Always consult your healthcare provider before starting or stopping any medication.
Major Highly clinically significant. Avoid combinations; the risk of the interaction outweighs the benefit.
Moderate Moderately clinically significant. Usually avoid combinations; use it only under special circumstances.
Minor Minimally clinically significant. Minimize risk; assess risk and consider an alternative drug, take steps to circumvent the interaction risk and/or institute a monitoring plan.
Unknown No interaction information available.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.